Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR4195683

—

71022744-b48a-5dcc-8529-490b89c884db

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.470
  • INTERFERON_ALPHA_RESPONSE+0.410
  • MYC_TARGETS_V1+0.410
  • G2M_CHECKPOINT+0.370
  • MYC_TARGETS_V2+0.300
  • APICAL_SURFACE+0.180
  • INTERFERON_GAMMA_RESPONSE+0.160
  • NOTCH_SIGNALING+0.150
  • ESTROGEN_RESPONSE_LATE+0.120
  • MITOTIC_SPINDLE+0.110

Top 10 suppressed

  • BILE_ACID_METABOLISM-0.390
  • TNFA_SIGNALING_VIA_NFKB-0.320
  • ANGIOGENESIS-0.310
  • IL6_JAK_STAT3_SIGNALING-0.310
  • ANDROGEN_RESPONSE-0.280
  • HYPOXIA-0.280
  • XENOBIOTIC_METABOLISM-0.260
  • TGF_BETA_SIGNALING-0.200
  • CHOLESTEROL_HOMEOSTASIS-0.180
  • COMPLEMENT-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-E9-A247-01A-11R-A169-07
breast-umap@18
—B0.737
2ULC0564T_S96
lung-landscapes@6
—cohortA10.734
3SRR650192
bladder-landscape@3
——0.719
4TCGA-EW-A1PC-01B-11R-A21T-07
breast-umap@18
—C0.718
5TCGA-CN-5367-01A-01R-1436-07
head-neck@1
——0.716
6C3L-00927
lung-landscapes@6
—cohortSQ10.704
7TCGA-63-A5ML-01A-31R-A27Q-07
lung-landscapes@6
—cohortSQ20.703
8TCGA-NC-A5HG-01A-11R-A26W-07
lung-landscapes@6
—cohortSQ10.702
9BS_TGS109T3
brain-umap@2
high-grade glioma—0.700
10TCGA-OR-A5LC-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.697

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.470Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.410Inavolisib— uncovered
MYC_TARGETS_V10.410Inavolisib— uncovered
G2M_CHECKPOINT0.370Inavolisib— uncovered
MYC_TARGETS_V20.300Idelalisib— uncovered
APICAL_SURFACE0.180Temsirolimus— uncovered
INTERFERON_GAMMA_RESPONSE0.160Idelalisib— uncovered
NOTCH_SIGNALING0.150Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.120Idelalisib— uncovered
MITOTIC_SPINDLE0.110Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.100Inavolisib— uncovered
DNA_REPAIR0.090Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.090Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.090Remibrutinib— uncovered
PROTEIN_SECRETION0.090Remibrutinib— uncovered
KRAS_SIGNALING_DN0.080Remibrutinib— uncovered
APICAL_JUNCTION0.050Inavolisib— uncovered
MYOGENESIS0.050Inavolisib— uncovered
GLYCOLYSIS0.040Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.010Inavolisib— uncovered